Posts

Clinovo Presents Next Generation Cloud-based eClinical System at Venture Capital Conference

/in , /by


Sunnyvale, CA (PRWEB) February 05, 2014

Clinovo is a technology focused Contract Research Organization (CRO) headquartered in Sunnyvale, CA. Clinovo is seeking funds to launch CloudClinica, a disruptive cloud-based platform for clinical trials. Ale Gicqueau, President & CEO at Clinovo, will present his vision and strategy for CloudClinica to venture capitalists at the 30th Annual Investors Choice Venture Capital Conference. The event will be held on Thursday, February 6th in Salt Lake City, Utah.

The Annual Investors Choice Venture Capital Conference is organized by the Wayne Brown Institute (WBI). Venture capitalists from all over the United States will convene to learn about the best and brightest emerging IT and life science companies. In the last six years, technology start-ups that have gone through the Wayne Brown Institute (WBI) process have raised more than $ 632 million dollars in angel and venture capital. Clinovo will present CloudClinica among twenty innovative companies from the high-tech, life-science and clean-tech sectors.

CloudClinica is Clinovo’s next generation Cloud-based eClinical platform. CloudClinica is an easy-to-use, pay-as-you-go platform to build and manage clinical studies from the ground up without any programming skills. CloudClinica will remove IT dependency and allow small companies to access sophisticated eClinical systems. CloudClinica will bring an average 80% savings from existing solutions while meeting regulatory compliance requirements. Until today, the adoption of eClinical systems like EDC (Electronic Data Capture) has remained slow in some segments of clinical research. Only 40% of Phase I clinical trials had adopted EDC by the end of 2012. CloudClinica will broaden the use of eClinical systems and empower biotech, pharmaceutical, medical device, and diagnostic companies.

Clinovo is a pioneer in the field of eClinical systems with its advanced open source Electronic Data Capture (EDC) system ClinCapture. ClinCapture has been deployed in phase I to phase IV clinical studies, for pharmaceutical, medical device, diagnostic companies, and CROs. ClinCapture already features an integrated eClinical suite of modules, including easy-to-use randomization, ePRO (Patient Reported Outcomes), CTMS (Clinical Trials Management System), and offline data entry. Clinovo recently unveiled its new medical coding module at the Outsourcing in Clinical Trials West Coast Conference in Burlingame, CA, greatly improving clinical data consistency and interoperability.

Contact information

Sophie McCallum

Director of Operations, Clinovo

408-773-6258

sophie.mccallum(at)clinovo(dot)com

About Clinovo

Clinovo is a technology focused Contract Research Organization (CRO) headquartered in the Silicon Valley. Clinovo streamlines clinical trials for life science companies globally by developing validated, intuitive open source eClinical systems. Clients claim over 50% cost savings using Clinovo’s open source Electronic Data Capture (EDC) system ClinCapture, and CDISC Express, the first open source CDISC conversion tool. Services also include Biometrics Services, Staffing Solutions, and TechTrainings.







Dr. Tomasz Sablinski to Deliver Keynote at 2012 OpenClinica Conference

/in , /by


Waltham, Massachusetts (PRWEB) February 13, 2012

Headlining this years OpenClinica Global Conference is Dr. Tomasz Sablinski, a leading clinical research innovator who is challenging the current model of drug development. Dr. Sablinski will talk about how barriers to delivering new medical treatments via clinical development can be overcome by borrowing from contemporary concepts of transparency, crowd sourcing, and open innovation.

Dr. Sablinskis perspective reflects his 30+ years working as a practicing physician, basic researcher, drug developer, investor, and entrepreneur. During this time, has served as a researcher at Harvard Medical School, a Medical Director at Parexel, VP of Clinical Development at Novartis, and Head of Development and Managing Director at private equity firm Celtic Therapeutics.

According to Dr. Sablinski, The emerging clinical development crisis requires a re-thinking of the entire process. Those organizations flexible enough to adapt by redesigning the way clinical trials are conceived and conducted using advances in communications and telemedicine, along with open innovation principles, will, I believe, prevail in the long run.

Dr. Sablinski believes we are at an inflection point–the persistent poor productivity of existing clinical approaches provides a unique opportunity for bringing much- needed innovation to the clinical trials industry.

We are thrilled to have Dr. Tomasz Sablinski deliver the keynote address at this years OpenClinica conference, said Ben Baumann, Chair of the OpenClinica Conference Committee. His bold ideas will be sure to challenge many of our current assumptions in thought-provoking, even controversial ways. He is not afraid to question the status quo, and seeks to encourage much of the same type of disruptive innovation that OpenClinica strives to bring to clinical research.

More information about the 2012 OpenClinica Conference is available online at https://community.openclinica.com/conference.

About the 2012 OpenClinica Conference